# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $15 pr...
OptimizeRx (NASDAQ:OPRX) reported quarterly adjusted earnings of $0.26 per share which met the analyst consensus estimate. This...
JMP Securities analyst Constantine Davides initiates coverage on OptimizeRx (NASDAQ:OPRX) with a Market Outperform rating an...
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and maintains $13 price target.
RBC Capital analyst Sean Dodge reiterates OptimizeRx (NASDAQ:OPRX) with a Outperform and maintains $17 price target.
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...